HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines.

The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness.

The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021.

HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.